The Pro Medicus Ltd (ASX: PME) share price is up more than 1% after revealing another impressive contract win.
Pro Medicus describes itself as a leading healthcare informatics company, providing a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups globally.
A$16 million contract renewal
Pro Medicus reported that it has signed a five year, A$16 million contract renewal (including the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging), with The Ohio State University Wexner Medical Center (OSUWMC).
The ASX share noted that OSUWMC is a large multi-disciplinary academic medical center located in Columbus, Ohio.
It employs approximately 22,000 staff, 2,000 physicians, with 1,400 inpatient beds, across six hospitals. It’s also the teaching hospital for The Ohio State University College of Medicine.
Pro Medicus said that the renewal was negotiated with increased minimums and an increased fee per transaction.
Management comments
The Pro Medicus CEO Dr Sam Hupert said:
OSUWMC provides world class, acclaimed patient care. Renewing this contract, to now include the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging, confirms our belief that we have extensive native capabilities that Visage customers appreciate as they seek to retire legacy solutions and continue to scale their Visage 7 Enterprise Imaging Platform.
This contract brings our total renewals for the financial year to A$141M, maintaining our track record of client retention. This underpins our belief that our solution provides unparalleled return on investment from both a financial and a clinical perspective.
Final thoughts on the Pro Medicus share price
The Pro Medicus share price is still down heavily over the last year, though it has risen 31% from 14 May 2026.
The company can’t control how negative or positive the market is about Pro Medicus or technology businesses in general. But, I think the market became overly negative on the quality of the business and its long-term prospects.
It continues winning contract renewals at an increased fee per transaction, which suggests organic growth, along with the new contracts it’s winning. New revenue is coming at a high profit margin, which is great for shareholders.
I think it’s still one of the high-quality ASX growth shares to keep an eye on.
